Etcamah in Combination With a CDK4/6 Inhibitor Approved in the U.S. for 1st-line Advanced HR-positive Breast Cancer
September 05, 2026
September 05, 2026
WILMINGTON, Delaware, Sept. 5 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ETCAMAH(R) (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation
Innovative treatmen . . .
* * *
ETCAMAH(R) (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation
Innovative treatmen . . .